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New blood vessels arise from preexisting ones 
in the process of physiological angiogenesis, 
both during embryonic development and in 
the female reproductive cycle. In addition, 
angiogenic vessel growth is closely associated 
with the progression of various cancers and eye 
diseases (Welti et al., 2013). Thus, angiogen-
esis promotes the growth of solid tumors and 
their metastasis, whereas abnormal blood vessel 
growth in the eye impairs visual function. For 
example, abnormal choroidal angiogenesis is a 
pathological feature of the “wet” form of age-
related macular degeneration (AMD), whereas 
excessive retinal angiogenesis leads to vascular 
malformations that protrude into the vitre-
ous in patients with proliferative diabetic reti-
nopathy (PDR) or retinopathy of prematurity 
(ROP; Campochiaro, 2013).
The vascular endothelial growth factor A 
(VEGF) is a key mediator of both physiological 
and pathological angiogenesis and a validated 
target for anti-angiogenesis therapy in the clinic 
(Kim and D’Amore, 2012; Welti et al., 2013). 
For example, anti-VEGF therapy stabilized 
sight in >90% and significantly improved vi-
sion in 30% of patients with wet AMD over a 
2-yr treatment period (Rosenfeld et al., 2006). 
However, the efficacy of anti-VEGF in AMD 
has been mainly attributed to reduced vascular 
leak rather than to an effect on neoangiogenesis 
(Campochiaro, 2013). The incomplete sensitiv-
ity of pathological eye vessels to anti-VEGF 
therapy may suggest that VEGF-independent 
pathways also contribute to ocular angiogene-
sis. Moreover, long-term anti-VEGF treatment 
has been proposed to pose likely risks, as pre-
clinical studies for several different eye diseases 
revealed excessive neuronal cell death in the 
retina after VEGF blockade (Nishijima et al., 
2007; Saint-Geniez et al., 2008; Foxton et al., 
2013). Yet clinical data from long-term studies 
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To enable new blood vessel growth, endothelial cells (ECs) express neuropilin 1 (NRP1), and 
NRP1 associates with the receptor tyrosine kinase VEGFR2 after binding the vascular endo-
thelial growth factor A (VEGF) to enhance arteriogenesis. We report that NRP1 contributes 
to angiogenesis through a novel mechanism. In human and mouse ECs, the integrin ligand 
fibronectin (FN) stimulated actin remodeling and phosphorylation of the focal adhesion 
component paxillin (PXN) in a VEGF/VEGFR2-independent but NRP1-dependent manner. 
NRP1 formed a complex with ABL1 that was responsible for FN-dependent PXN activation 
and actin remodeling. This complex promoted EC motility in vitro and during angiogenesis on 
FN substrates in vivo. Accordingly, both physiological and pathological angiogenesis in the 
retina were inhibited by treatment with Imatinib, a small molecule inhibitor of ABL1 which 
is widely used to prevent the proliferation of tumor cells that express BCR-ABL fusion 
proteins. The finding that NRP1 regulates angiogenesis in a VEGF- and VEGFR2-independent 
fashion via ABL1 suggests that ABL1 inhibition provides a novel opportunity for anti- 
angiogenic therapy to complement VEGF or VEGFR2 blockade in eye disease or solid  
tumor growth.
© 2014 Raimondi et al. This article is distributed under the terms of an 
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first 
six months after the publication date (see http://www.rupress.org/terms). After 
six months it is available under a Creative Commons License (Attribution– 
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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et al., 2009), we first examined the requirement of NRP1 for 
EC adhesion, spreading, and actin remodeling. For these ex-
periments, we used human dermal microvascular ECs (HD-
MECs) because dermal vasculature naturally undergoes extensive 
angiogenesis during wound healing. We additionally used 
human umbilical vein ECs (HUVECs), as they have been widely 
used to study VEGF-induced signaling mechanisms (e.g., Soker 
et al., 2002; Pan et al., 2007a; Chen et al., 2010). We trans-
fected primary cells with a previously validated siRNA that 
targets NRP1 or a control nonsense siRNA. Having confirmed 
the efficacy of this approach (Fig. 1 A), we tested HDMEC 
and HUVEC adhesion to tissue culture dishes coated with 
10 µg/ml FN, a concentration which effectively promotes cell 
adhesion and migration (Clark et al., 1986; Sottile et al., 1998; 
Tvorogov et al., 2005). In contrast to earlier studies, which 
reported that NRP1 loss inhibits HUVEC adhesion at FN 
concentrations <5 µg/ml (Murga et al., 2005; Valdembri et al., 
2009), we found that adhesion was not compromised by 
NRP1 deficiency in either HDMECs or HUVECs at 10 µg/ml 
FN (Fig. 1, B and C). We had therefore identified conditions 
suitable to study FN-induced cell spreading, actin remodel-
ing, and cell migration of ECs in the absence of prior defects in 
cell attachment.
Phalloidin staining of filamentous (F) actin showed that 
NRP1-deficient HDMECs (Fig. 1, D and E) adopted an 
abnormal round morphology with abundant cortical actin 
when plated on FN (Fig. 1 F). In contrast, control cells ap-
peared elongated and contained stress fibers typical of adher-
ent cells (Fig. 1 F). VEGFR2 protein levels (Fig. 1 D) and 
mRNA expression (Fig. 1 E) were slightly but significantly 
decreased in NRP1-deficient cells, but cells transfected with 
siRNA targeting VEGFR2 spread well on FN and assembled 
many stress fibers (Fig. 1 F), indicating that cytoskeletal de-
fects in NRP1-deficient cells were not caused by low VEGFR2 
expression. High magnification images revealed phalloidin-
positive, filopodia-like microspikes in HDMECs 60 and 120 min 
after plating on FN, which were significantly reduced after 
NRP1 but not VEGFR2 down-regulation (Fig. 1 F, right 
columns). Quantitation confirmed that NRP1 but not VEGFR2 
down-regulation significantly impaired cell spreading (Fig. 1 G) 
and microspike extension (Fig. 1 H) in cells plated on FN. 
Strikingly, addition of VEGF165, which is known to bind 
both VEGFR2 and NRP1, did not rescue the cytoskeletal 
defects of FN-stimulated HDMECs lacking NRP1 (Fig. 1 I). 
NRP1 therefore functions independently of VEGF and 
VEGFR2 to regulate ECM-induced cell spreading and actin 
remodeling in ECs.
NRP1 promotes the motility and haptotactic  
migration of FN-stimulated ECs
Impaired cell spreading and actin remodeling in NRP1-deficient 
ECs predicts defective cell motility. By tracking the behavior 
of individual HDMECs after plating on FN, we indeed found 
that control cells were significantly more motile than cells 
lacking NRP1 (Videos 1 and 2; Fig. 1, J and K). Consistent with 
reduced motility, transwell assay measuring ECM-induced 
of patients with continuous anti-VEGF treatment are not 
available. These considerations, combined with the observa-
tion that tumor vessels can develop resistance to anti-VEGF 
therapy (Casanovas et al., 2005; Shojaei et al., 2007), highlight 
the need to identify effective anti-angiogenesis therapies that 
are based on VEGF-independent targets and can be used in 
combination with or independently of anti-VEGF therapy to 
improve outcome for patients.
Neuropilin 1 (NRP1) is a non-catalytic receptor for the 
VEGF165 isoform of VEGF that complexes with VEGFR2 to 
potentiate signal transduction in endothelial cells (ECs; e.g., 
Mamluk et al., 2002; Koch et al., 2011). Thus, the NRP1 cyto-
plasmic tail recruits a trafficking complex that directs VEGFR2 
along an endocytic pathway that prevents receptor dephos-
phorylation to augment MAPK signaling via ERK1 and ERK2 
(Salikhova et al., 2008; Ballmer-Hofer et al., 2011; Lanahan 
et al., 2013). This NRP1 function is essential for arteriogenesis, 
which depends on luminal vessel growth, but is dispensable for 
angiogenesis, driven by vessel sprouting, branching, and fusion 
(Fantin et al., 2011; Lanahan et al., 2013). Additionally, NRP1 
is able to interact with extracellular matrix (ECM) receptors of 
the integrin family independently of VEGFR2 (Murga et al., 
2005; Fukasawa et al., 2007; Valdembri et al., 2009). However, the 
relative significance of NRP1 for VEGF/VEGFR2-dependent 
versus integrin ligand-stimulated, but VEGFR2-independent 
processes for angiogenesis in vivo has not previously been de-
termined. Moreover, the intracellular pathways that may be 
regulated by NRP1 in a VEGF/VEGFR2-independent fash-
ion have, surprisingly, not yet been defined.
Here, we demonstrate that NRP1 promotes the phosphory-
lation of integrin targets such as paxillin (PXN) and concomi-
tant actin remodeling in fibronectin (FN)-stimulated human 
ECs. Rather than using VEGFR2, NRP1-dependent PXN ac-
tivation was found to rely on NRP1 association with ABL1, 
a nonreceptor tyrosine kinase with an actin-binding/bundling 
domain that links phosphoregulation to actin remodeling in a 
diverse range of cell types (Colicelli, 2010). Accordingly, knock-
down of NRP1 or ABL1 by siRNA technology or with genetic 
tools inhibited actin remodeling and PXN phosphorylation, 
and consequently the migration of human and mouse ECs on 
FN in vitro. Inhibition of ABL1 kinase activity with Imatinib, 
an FDA-approved drug used to treat cell proliferation in leuke-
mia caused by ABL1-BCR fusion protein, demonstrated simi-
lar effects on ECs in vitro and reduced vascular sprouting and 
branching on FN-rich templates during angiogenesis in vivo. 
Moreover, Imatinib treatment curbed pathological blood vessel 
growth in a mouse model of neovascular eye disease similarly 
to targeting NRP1 in ECs. ABL1 therefore presents a novel 
therapeutic opportunity for anti-angiogenic therapy.
RESULTS
NRP1 promotes spreading and actin remodeling  
of FN-stimulated ECs independently of roles  
in cell adhesion and VEGFR2
Because NRP1 is known to interact with FN-binding integ-
rins (Fukasawa et al., 2007; Robinson et al., 2009; Valdembri 
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phosphokinase antibody array (e.g., Zhuang et al., 2012). For 
this experiment, HDMECs were transfected with si-NRP1 or 
control siRNA (Fig. 2 A), and then serum-starved and stimu-
lated with VEGF165 (Fig. 2 B) or plated on FN (Fig. 2 C). 
We observed reduced VEGF165-induced activation of the 
MAPK p38 in ECs lacking NRP1, as expected (Kawamura 
et al., 2008), and additionally impaired FN-induced P38 acti-
vation in ECs lacking NRP1 (Fig. 2, B and C). The screen also 
showed that NRP1 down-regulation in VEGF165-stimulated 
HDMECs reduced AKT activation (Fig. 2 B), as previously 
reported for HUVECs (Pan et al., 2007a,b; Koch et al., 2011). 
Unexpectedly, however, NRP1 down-regulation did not impair 
AKT phosphorylation in FN-stimulated ECs (Fig. 2 C).
Consistent with findings in HUVECs and zebrafish 
(Lanahan et al., 2010, 2013), NRP1 loss decreased both 
VEGF165- and FN-induced activation of PLC1 (Fig. 2, 
B and C), known to promote the phosphorylation of the focal 
adhesion protein PXN downstream of FN-mediated integrin 
activation to increase cell spreading and migration (Choi 
et al., 2007; Zaidel-Bar et al., 2007). Consistent with reduced 
haptotaxis demonstrated reduced migration of NRP1-deficient 
compared with control cells toward FN, but VEGFR2 knock-
down did not affect migration (Fig. 1 L). Similar results were 
obtained with HUVECs (Fig. 1 L). To examine if NRP1 defi-
ciency impaired EC migration in another species, we used mouse 
lung ECs (MLECs) from Nrp1 conditional null (Nrp1fl/fl) 
mice in the transwell assay after infecting them with adenovi-
rus expressing GFP as a control or CRE recombinase to down-
regulate NRP1 (Fig. 1 M). As observed for human ECs, 
migration onto FN substrates was significantly reduced in 
MLECs lacking NRP1 compared with controls (Fig. 1 N). 
NRP1 deficiency therefore impairs ECM-induced EC mo-
tility and migration independently of VEGFR2 in a pathway 
that is conserved between mice and humans.
Identification of NRP1-dependent, ECM-induced signal 
transduction pathways
Because FN stimulation activated NRP1-dependent actin re-
modeling and cell migration independently of VEGF165 and 
VEGFR2, we sought to identify candidate effectors with a 
Figure 1. NRP1 is dispensable for cell ma-
trix adhesion but promotes FN-induced cell 
spreading, filopodia extension, and motility 
of primary ECs. (A–C) Immunoblotting with the 
indicated antibodies to demonstrate NRP1 
knockdown (A) and time course of cell adhesion 
(B and C) in HDMECs and HUVECs transfected 
with control or NRP1 siRNA and plated for the 
indicated times on plastic dishes coated with  
10 µg/ml FN (mean ± SEM of 3 independent 
experiments). (D–H) HDMECs transfected with 
control, VEGFR2 or NRP1 siRNA were plated on 
FN for the indicated times before immunoblot-
ting (D), qPCR analysis (E) or fluorescent labeling 
(F) with the F-actin marker phalloidin (green) and 
the nuclear counterstain DAPI (blue). Bar, 20 µm. 
Images shown in the right two columns are 
higher magnifications of areas indicated with 
dotted squares. Also shown is a quantification of 
cell area (G) and phalloidin-stained microspikes 
(H) at the indicated time points (mean ± SEM of 
≥30 cells from 3 independent experiments).  
(I) HDMECs transfected with si-NRP1 were plated 
on FN in the presence of 50 ng/ml VEGF165 for 
the indicated times before fluorescent labeling 
with phalloidin (green) and DAPI (blue). Bar,  
20 µm. (J and K) HDMECs transfected with con-
trol or NRP1 siRNAs were plated on FN and cell 
motility on FN observed for 200 min. J shows 
representative tracks, with the point of origin of 
each cell plotted as 0 at the axis intersection.  
K shows mean track length (mean ± SEM of 23 
cells from 2 independent experiments). (L–N) 
HDMECs or HUVECs transfected with control, 
VEGFR2 or NRP1 siRNA (L) and Nrp1fl/fl MLECs 
transfected with adenovirus carrying Gfp control 
or Cre transgenes (M and N) were plated on FN-coated transwells. The number of transmigrated cells was determined after 240 min (mean ± SEM from ≥3 experi-
ments, each performed in duplicate). Asterisks indicate statistical significance: *, P < 0.05; **, P < 0.01; ***, P < 0.001, Student’s t test.
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induce comparable VEGFR2 stimulation (Fig. 2 E). Also 
as expected, NRP1 or VEGFR2 knockdown decreased 
VEGF165-induced AKT phosphorylation; however, FN- 
induced AKT phosphorylation was unaffected by NRP1 or 
VEGFR2 deficiency (Fig. 2, D and E). The AKT pathway 
therefore transduces growth factor but not ECM signals in a 
VEGFR2- and NRP1-dependent fashion. Agreeing with ex-
periments in other types of ECs (Pan et al., 2007a; Lanahan 
et al., 2010; Ren et al., 2010), VEGF165-induced ERK1/2 
phosphorylation was impaired after NRP1 or VEGFR2 
knockdown in HDMECs (Fig. 2, D and F). Surprisingly, 
however, ERK1/2 phosphorylation was significantly in-
creased in response to FN (Fig. 2, E and F). Finally, we used 
immunoblotting to examine how NRP1 and VEGFR2 
knockdown affected PXN tyrosine phosphorylation. Although 
NRP1 loss reduced PXN phosphorylation in FN-stimulated 
HDMECs, VEGFR2 knockdown did not (Fig. 2 E). In con-
trast, PXN was constitutively phosphorylated in adherent 
HDMECs, with phosphorylation increasing slightly after 
VEGF165 stimulation in a VEGFR2-dependent manner 
(Fig. 2 D; Birukova et al., 2009), but NRP1 was not required 
for VEGF165-induced PXN phosphorylation (Fig. 2 D). 
Together with the phosphoantibody screen, these findings dem-
onstrate that ECM- and VEGF165-induced signal transduc-
tion pathways are differentially affected by NRP1 loss, and 
that NRP1-dependent PXN phosphorylation occurs inde-
pendently of VEGFR2.
PLC1 activation and a requirement for NRP1 in integrin 
ligand-mediated EC spreading and motility, PXN phosphory-
lation on tyrosine residue (Y) 118 was also reduced in FN-
stimulated HDMECs lacking NRP1 (Fig. 2 C). In contrast, 
VEGF165-induced PXN phosphorylation was unaffected by 
NRP1 loss (Fig. 2 B). Loss of NRP1 did not affect the phos-
phorylation of FAK on residue Y397 downstream of either 
VEGF or FN (Fig. 2 B). This was unexpected, as phosphory-
lation of this residue activates FAK kinase, which is then able 
to phosphorylate PXN (Chen et al., 1996; Parsons et al., 
2000). Collectively, the phosphoantibody screen indicated 
essential and distinct roles for NRP1 in VEGF165- versus 
ECM-stimulated signal transduction and suggested that NRP1 
promotes PXN phosphorylation downstream of ECM acti-
vation independently of VEGFR2 or FAK.
Differential dependency of ECM signaling pathways  
on NRP1 and VEGFR2
Immunoblotting validated the results from the phosphoanti-
body screen and allowed us to more directly compare NRP1 
and VEGFR2 dependence of specific signal transduction path-
ways (Fig. 2, D and E). For these experiments, HDMECs 
were serum-starved and plated on FN or grown on tissue 
culture plastic, serum-starved, and then stimulated with 
VEGF165. As expected, VEGF165-induced VEGFR2 phos-
phorylation was inhibited by NRP1 or VEGFR2 down- 
regulation (Fig. 2 D). In contrast, FN stimulation did not 
Figure 2. NRP1 transduces ECM signals independently of VEGF165 and VEGFR2. (A–C) For phosphoproteomic screening, HDMECs were transfected with 
control or NRP1 siRNA before immunoblotting to confirm NRP1 knockdown (A) or stimulation with VEGF165 for 10 min (B) or FN for 30 min (C), followed by  
phosphokinase-antibody array screening. Phosphorylation of the indicated proteins in si-NRP1 relative to si-control transfected cells from 2 independent experiments, 
performed in duplicate each, were shown as mean fold change ± SEM. (D and E) To validate NRP1-regulated phosphoproteins identified in the phosphoproteomic 
screen, HDMECs were transiently transfected with control, NRP1 or VEGFR2 siRNA and stimulated with VEGF165 (D) or plated on FN (E) for the indicated times. 
Lysates were immunoblotted for the indicated proteins, with GAPDH serving as a loading control. Immunoblots are representative of 3 independent experiments.  
(F) pERK (T202/Y204) levels were quantified as pixel intensity relative to GAPDH and values expressed as mean fold change ± SEM. *, P < 0.05, Student’s t test.
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Pasapera et al., 2010) and NRP1-deficient ECs have reduced 
pPXN (Figs. 1 and 2), we examined NRP1-dependent pPXN 
localization in FN-stimulated HDMECs by immunostaining. 
In control cells, pPXN increased over time and was present in 
NRP1, not VEGFR2, is required for ECM-induced PXN 
phosphorylation and focal adhesion localization
Because pPXN is recruited to focal adhesions to promote 
their turnover during cell migration (Zaidel-Bar et al., 2007; 
Figure 3. NRP1 promotes FN-induced PXN Y118 phosphorylation. (A and B) HDMECs transiently transfected with control, NRP1 or VEGFR2 siRNA 
were plated on FN for the indicated times and immunofluorescently labeled (A) for pPXN Y118 (green) together with phalloidin (red) and DAPI (blue; bar,  
20 µm) or immunoblotted for the indicated proteins (B). The single channel for pPXN staining is shown on the right side of A. (C) pPXN Y118 levels in immuno-
blots from 4 independent experiments were quantified as pixel intensity relative to GAPDH and values expressed as mean fold change ± SD in si-VEGFR2 or si- 
NRP1 relative to control siRNA transfected cells. *, P < 0.05, Student’s t test. (D) To examine if NRP1 forms a complex with pPXN in FN-stimulated ECs, 
HDMECs were detached in serum-free medium (nonadherent, NA) or plated on FN for the indicated times and then immunoprecipitated with control IgG or 
NRP1 antibodies, followed by immunoblotting for NRP1 and pPXN Y118. The immunoblot is representative of 4 independent experiments. (E) Single confocal 
scans of HDMECs plated on FN for 45 min and then immunofluorescently labeled with antibodies specific for human NRP1 or pPXN Y118 and counterstained 
with DAPI. Bar, 10 µm. A higher magnification of the area indicated with a dotted square is shown in the bottom row, and single channels for NRP1 and 
pPXN are shown adjacent to the triple stains at low and high magnification. Arrowheads indicate examples of partial colocalization. (F) HDMECs were trans-
fected with pCDNA3.1 encoding wild-type mouse NRP1 or mutant mouse NRP1D320A, plated on FN for 60 min, and then labeled with antibodies specific for 
mouse NRP1 and pPXN and counterstained with DAPI. The single channel for pPXN staining is shown on the right. Cells expressing murine NRP1 (white ar-
rowheads) up-regulate pPXN. Note that the antibody does not detect endogenous human NRP1 in untransfected cells (clear arrowheads). Bar, 20 µm.
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Figure 4. ABL1 knockdown impairs PXN Y118 phosphorylation and EC migration. (A) qPCR analysis for Abl1 expression in HDMECs. Abl1 values 
were normalized to Actb and expressed as fold reduction in knockdown relative to control HDMECs (mean ± SD of 3 independent experiments). ***, P < 0.001, 
Student’s t test. (B–E) Immunofluorescence labeling (B and C) and immunoblotting (D and E) of HDMECs transfected with si-ABL1 or control siRNA and 
then plated on FN for the indicated times. In B, pPXN Y118 (green) is shown together with phalloidin (red) and DAPI (blue) on the left, and as single chan-
nel in grayscale on the right. Bars, 20 µm. The pixel intensity of the pPXN signal was quantified in C as fold change in knockdown cells at the indicated 
time points relative to control cells at 60 min (mean ± SEM of 4 independent experiments). *, P < 0.05, Student’s t test. (D and E) Immunoblotting shows 
that ABL1 down-regulation reduces PXN, but not ERK1/2 phosphorylation. pCRKL served as readout for ABL1 down-regulation and GAPDH as a loading 
control. The quantitation of pPXN Y118 levels as pixel intensity after densitometry is shown in E. Values are expressed as fold change in knockdown cells 
at the indicated time points relative to nonadherent (NA) control cells at 0 min (mean ± SD of 3 independent experiments). *, P < 0.05, Student’s t test.  
(F) HDMECs transfected with control or ABL1 siRNA were plated on FN-coated transwells and the percentage of transmigrated HDMECs determined after 
240 min in knockdown relative to control cells (mean ± SEM in 4 independent experiments). **, P < 0.01, Student’s t test. (G and H) To investigate if ABL1 
and NRP1 form a constitutive protein complex in ECs and associate with pPXN in FN-stimulated cells, HEK cells were transfected with expression vectors 
for NRP1 and ABL1 (+) before immunoprecipitation with control IgG or ABL1 antibody and immunoblotting for NRP1 (G), or immunoprecipitation with 
NRP1 and immunoblotting for ABL1 (H). Nontransfected cells () were used as internal negative control. (I) To examine complex formation of endog-
enous NRP1, ABL1, and pPXN, HDMECs were detached and lysed (nonadherent, NA) or lysed after plating on FN for the indicated times. Lysates were 
immunoprecipitated with control IgG or ABL1 antibody followed by immunoblotting for NRP1 and pPXN Y118. (J and K) To examine if ABL1 recruits pPXN 
in a NRP1-dependent manner after FN stimulation, neonatal Nrp1fl/fl mice were induced with vehicle (control) or tamoxifen to delete NRP1 (J) and iso-
lated MLECs cultured on FN before being detached and lysed (A) or lysed after plating on FN for the indicated times. Lysates were immunoprecipitated 
with IgG or ABL1 antibody and immunoblotted for NRP1 and pPXN Y118 (K).
focal adhesions at the end of F-actin stress fibers, correlat-
ing with an elongated cell shape (Fig. 3 A). FN-stimulated 
HDMECs, therefore, displayed the hallmarks of polarized cells. 
Although VEGFR2 down-regulation did not impair these 
responses, HDMECs lacking NRP1 displayed their charac-
teristic rounded morphology with abundant cortical actin; 
correlating with the lack of stress fibers, pPXN levels were 
significantly decreased, with remaining pPXN being localized 
mainly to the cell periphery (Fig. 3, A and B). Immunoblot-
ting established that siRNA targeting had been effective and 
further confirmed reduced pPXN in NRP1-deficient cells 
(Fig. 3 B); in contrast, pPXN was slightly but significantly 
increased in VEGFR2-deficient cells (Fig. 3, B and C). These 
findings demonstrate that NRP1 promotes PXN phosphory-
lation in a VEGFR2-independent fashion.
Because both the phosphoantibody screen and immuno-
blotting suggested a functional relationship between NRP1 
and pPXN, we examined if both proteins interact. In agree-
ment, NRP1 immunoprecipitation, followed by pPXN im-
munoblotting, demonstrated an FN-dependent interaction in 
HDMECs (Fig. 3 D). Moreover, immunofluorescence showed 
partial colocalization in peripheral cell areas resembling focal 
adhesions (Fig. 3, E and F). The finding that NRP1 and pPXN 
associate in FN-stimulated ECs agrees with a study showing 
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(Cui et al., 2009; Baruzzi et al., 2010). Furthermore, the Y118 
residue that is phosphorylated in an NRP1-dependent fash-
ion resides in an ABL1 phosphorylation consensus site (Cujec 
et al., 2002), and ABL1 is an effector of NRP1 and integrins 
in tumor matrix remodeling (Yaqoob et al., 2012). To investi-
gate ABL1 function in FN-stimulated ECs, we used two in-
dependent but complementary methods: siRNA-mediated 
knockdown of ABL1 (Fig. 4) and pharmacological inhibition 
of ABL1 kinase activity (Fig. 5).
ABL1 knockdown was achieved by transfecting HDMECs 
with control siRNA or siRNA targeting ABL1 (si-ABL1) 
and confirmed by qPCR (Fig. 4 A). We found that target-
ing ABL1 caused a phenotype similar to NRP1 knockdown. 
Thus, immunostaining revealed significantly reduced pPXN 
levels, with residual pPXN accumulating in the cell periphery 
(Fig. 4, B and C). Moreover, there was a conspicuous absence 
of pPXN-positive focal adhesion contacts and stress fibers, 
but abundant cortical actin, correlating with impaired cell 
spreading and a round rather than elongated cell shape, as 
observed after NRP1 knockdown (Fig. 4 B). Immunoblot-
ting for the phosphorylated form of the ABL1 target CRKL 
(Lewis et al., 1996) confirmed ABL1 down-regulation as 
well as significantly reduced FN-stimulated pPXN in ABL1 
knockdown compared with control cells (Fig. 4, D and E). 
that overexpressed NRP1 colocalizes with 51 integrins at 
endothelial adhesion sites (Valdembri et al., 2009).
To examine the relationship between NRP1 and pPXN 
in a gain-of-function experiment, we transfected a construct 
encoding murine NRP1 into HDMECs and validated NRP1 
overexpression with an antibody specific for murine NRP1 
(Fig. 3 F). This experiment demonstrated increased PXN 
phosphorylation after FN stimulation in transfected com-
pared with neighboring untransfected cells (Fig. 3 F, top). 
Importantly, overexpressing a VEGF165 binding-deficient 
NRP1 mutant (mNRP1D320A; Herzog et al., 2011) similarly 
increased PXN phosphorylation (Fig. 3 F, bottom), confirm-
ing that FN/NRP1-dependent pPXN induction does not 
depend on VEGF binding to NRP1. Collectively, these re-
sults establish that NRP1 regulates PXN phosphorylation 
independently of VEGF.
ABL1 is essential for ECM-induced PXN phosphorylation
Because NRP1 lacks catalytic activity, it requires a partner 
kinase to promote FN-induced PXN phosphorylation, but 
this kinase is not VEGFR2 (Fig. 1) or FAK (Fig. 2, B and C). 
A good candidate is the cell adhesion–associated kinase ABL1, 
which interacts with PXN in FN-stimulated fibroblasts 
(Lewis and Schwartz, 1998) as well as integrins 1 and 2 
Figure 5. ABL1 kinase activity is essential for PXN Y118 phosphorylation in HDMECs in vitro. (A–C) To examine if ABL1 kinase activity is essen-
tial for PXN phosphorylation, we performed immunofluorescence labeling (A and B) and immunoblotting (C) of HDMECs treated with vehicle or Imatinib 
30 min before and during plating on FN for the indicated times. In A, pPXN Y118 (green) is shown together with phalloidin (red) and DAPI (blue) on the 
left and as single channel in grayscale on the right. Bars, 20 µm. pPXN pixel intensity was quantified in B and expressed as fold change in knockdown cells 
at the indicated time points relative to control cells at 60 min (mean ± SD of 4 independent experiments). *, P < 0.05, Student’s t test. (C) Immunoblotting 
confirmed that Imatinib treatment reduced pPXN Y118 levels. Total ERK1/2 levels were used as a loading control. (D) To examine if endogenous NRP1 and 
ABL1 form a complex in ECs, we performed coimmunoprecipitation of endogenous proteins from lysates of HDMECs, treated with vehicle or 10 µM 
Imatinib for 30 min, detached, and plated on FN for the indicated times in the presence of Imatinib. Immunoprecipitation using ABL1 antibody was fol-
lowed by immunoblotting performed for NRP1 and ABL1.
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Imatinib (Glivec), a small molecule inhibitor that effectively 
targets ABL1 but not VEGFR2 (Buchdunger et al., 2002; 
Anselmi et al., 2012) and has been approved for therapy in 
cancers with up-regulated ABL1 kinase activity (Druker et al., 
1996). As observed in si-ABL1–transfected cells, Imatinib-
treated HDMECs formed few stress fibers, but abundant cor-
tical actin, and they adopted a round shape with reduced cell 
spreading; moreover, they had low pPXN phosphorylation, with 
residual pPXN in the cell periphery rather than in areas where 
stress fibers normally terminate in focal adhesions (Fig. 5 A). The 
quantitation of pixel intensities in immunostains (Fig. 5 B) and 
immunoblots (Fig. 5 C) confirmed significantly reduced PXN 
phosphorylation in Imatinib-treated compared with control 
cells. NRP1 immunoprecipitation of Imatinib-treated HDMECs 
followed by ABL1 immunoblotting showed that both pro-
teins formed a complex before FN stimulation, independently 
of ABL1 kinase activity (Fig. 5 D). We conclude that ABL1 
stimulates PXN phosphorylation in an NRP1-dependent fash-
ion when ECs migrate on FN.
NRP1 regulates ABL1-mediated PXN phosphorylation  
in retinal angiogenesis
To examine if NRP1 and ABL1 also promote PXN phosphoryl-
ation in an ECM-dependent angiogenesis model in vivo, 
we studied the perinatal mouse retina; in this organ, endothe-
lial sprouts headed by filopodia-studded tip cells migrate to-
ward astrocyte-localized VEGF in the retinal periphery, with 
filopodia being guided by astrocyte-derived FN (Fig. 6 A; 
Ruhrberg et al., 2002; Gerhardt et al., 2003; Stenzel et al., 
2011). Immunostaining confirmed FN deposition around 
IB4-stained vessels and ahead of the vascular front in a fine 
meshwork characteristic of astrocytes (Fig. 6 B). To investi-
gate how NRP1 deficiency affected pPXN levels during reti-
nal angiogenesis, we could not use Nrp1/ mice, as they die 
before birth (Kawasaki et al., 1999). Instead, we compared 
Nrp1+/+ and Nrp1+/ littermates because the latter are viable 
but nevertheless have mild angiogenesis defects (Fantin et al., 
2013). Immunoblotting confirmed significantly decreased 
NRP1 levels in P6 Nrp1+/ mice (Fig. 6 C). Single optical 
slices, acquired by confocal microscopy after immunolabeling, 
revealed pPXN staining in ECs at the IB4-positive vascular 
front, including tip cells and their filopodia, and also some 
pPXN ahead of the vascular front (Fig. 6 D). As observed for 
si-NRP1–targeted HDMECs, pPXN staining appeared re-
duced in Nrp1+/ littermates, both in vascular and avascular 
areas (Fig. 6 D). To confirm that this defect was cell autono-
mous in vascular endothelium, we also used Cre-LoxP recom-
bination approach to delete NRP1 (Fig. 1). Thus, conditional 
Nrp1-null mice lacking or expressing a tamoxifen-inducible, 
endothelial-specific Cre transgene were treated with tamoxi-
fen from postnatal day 2 (P2) to P5 and stained for IB4 and 
pPXN. As seen in Nrp1+/ mice, tamoxifen-treatment reduced 
pPXN in Cre-expressing but not Cre-negative (control) lit-
termates (Fig. 6 D).
To quantify pPXN specifically in ECs, we isolated IB4-
positive areas by applying a virtual mask over IB4-negative 
This analysis also showed increased ERK1/2 phosphorylation 
after ABL1 knockdown (Fig. 4 D), similar to NRP1 knock-
down (Fig. 2, E and F). Unexpectedly, NRP1 protein expres-
sion also decreased in a time-dependent manner after ABL1 
knockdown (Fig. 4 D), but this decrease was not caused by 
reduced NRP1 mRNA levels (si-ABL1 relative to si-control: 
1.18 ± 0.13 at 0 min; 1.17 ± 0.11 at 30 min; 1.07 ± 0.07 at 
60 min; mean ± SD; n = 3; P > 0.05). ABL1 therefore posi-
tively regulates NRP1 protein stability in HDMECs in response 
to FN stimulation. Hence, ABL1 may affect NRP1-dependent 
pPXN up-regulation in a dual fashion, first by directly promot-
ing PXN phosphorylation, and second by stabilizing NRP1 
protein and therefore increasing the capacity of HDMECs to 
respond to FN and up-regulate PXN phosphorylation via an 
NRP1-dependent pathway.
Because PXN phosphorylation promotes the turnover 
of focal adhesions that serve as traction points during cell 
migration (Zaidel-Bar et al., 2007), we predicted that ABL1 
loss would impair EC migration on FN. In agreement, a 
transwell assay showed a 40% reduction in haptotactic mi-
gration after ABL1 knockdown (Fig. 4 F), which was similar 
to the reduction observed after NRP1 knockdown (Fig. 1, 
K and L). NRP1 and ABL1 therefore similarly regulate PXN 
phosphorylation, actin remodeling, and cell migration in 
FN-stimulated ECs.
ABL1 forms a complex with NRP1 in ECs
The similar cellular changes caused by ABL1 and NRP1 defi-
ciency raised the possibility that both proteins interact to regulate 
PXN phosphorylation. To investigate this idea, we cotransfected 
HEK293 cells with expression constructs for NRP1 and ABL1. 
ABL1 immunoprecipitation followed by NRP1 immunoblot-
ting, and vice versa, showed that both proteins formed a complex 
(Fig. 4, G and H). Immunoprecipitating ABL1 from HDMECs 
followed by NRP1 immunoblotting confirmed the existence of 
an endogenous complex and further showed that this complex 
had recruited pPXN 60 min after FN stimulation (Fig. 4 I). To 
investigate whether this complex also forms in murine ECs, we 
inactivated two conditional Nrp1-null alleles in newborn mice 
with a tamoxifen-inducible endothelial Cre transgene (Fantin 
et al., 2013) and then isolated ECs (Fig. 4 J). As observed for 
HDMECs, ABL1 immunoprecipitated NRP1 in control MLECs 
adhering to FN, and complex formation was increased after de-
taching the cells and plating them for 30 min on FN (Fig. 4 K). 
Moreover, pPXN was present in the ABL1–NRP1 complex of 
MLECs from both conditions (Fig. 4 K), as seen in HDMECs 
(Fig. 4 I). In contrast, NRP1 was not immunoprecipitated effec-
tively in MLECs from tamoxifen-treated mice, and complex for-
mation of ABL1 with pPXN was reduced (Fig. 4 K). These data 
demonstrate that ABL1 and NRP1 form a complex and that 
ABL1 recruits pPXN in an NRP1-dependent fashion.
ABL1 kinase inhibition reduces ECM-induced  
PXN phosphorylation
To examine if ABL1 kinase activity was required for FN- 
induced PXN phosphorylation, we treated HDMECs with 
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vascular front of heterozygous Nrp1-null mutants (Fig. 6 E) 
and endothelial-specific Nrp1-null mutants (Fig. 6 F) com-
pared with controls.
areas (Fig. 6 D, right). Quantification of pPXN relative to 
IB4 pixel intensity in masked 3D projections of z-stacks 
showed significantly reduced endothelial pPXN staining at the 
Figure 6. NRP1 and ABL1 promote PXN phosphorylation during retinal angiogenesis in the mouse. (A) A schematic representation of retinal 
angiogenesis illustrates how vessels (red) expand from the retinal center toward the periphery (indicated by arrows). Vessels are guided by an astrocyte-
derived FN network (green) ahead of the vascular front, but FN subsequently overlaps partially with the vessel pattern (red with green outline). (B) Immuno-
labeling for FN together with the vascular marker IB4 demonstrates angiogenesis in the P6 retina. Bar, 400 µm. The area shown in higher magnification is 
indicated with a dotted square in the first panel. (C) Reduced NRP1 levels in Nrp1+/ compared with Nrp1+/+ littermates, shown by immunoblot quantifi-
cation of NRP1 protein levels in P6 lungs. NRP1 levels were normalized to VE-cadherin levels and expressed as percentage relative to wild type (mean ± 
SEM; n ≥ 3). *, P < 0.05, Student’s t test. (D–H) Single confocal slices through the vascular front in retinas of Nrp1+/+, Nrp1+/ littermate mice and tamoxi-
fen-inducible EC-specific Nrp1-null mice injected with tamoxifen from P2 to P5 (D) or treated with vehicle or 100 mg/kg/d Imatinib on days P4 and P5 
(G). Retinas were immunostained for pPXN Y118 and IB4. Bar, 15 µm. In D and G (right), Imaris software was used to mask areas not labeled for IB4 to 
reveal pPXN staining in ECs. Quantification of vascular pPXN in optical z-stacks after applying a mask to isolate IB4-positive areas in Nrp1+/ (E),  
tamoxifen-inducible EC-specific Nrp1-null mutants (F), and Imatinib-treated mice (H) relative to controls. Mean pixel values of pPXN relative to IB4 are 
expressed as percentage of control ± SEM (n = 3). *, P < 0.05, Student’s t test.
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and Imatinib dose-dependent reduction in branch points be-
hind the vascular front, indicative of reduced sprout fusion 
(Fig. 7 G). These findings therefore agree with the recently 
shown requirement of actin-based filopodia dynamics for 
sprout fusion and therefore vascular network formation (Phng 
et al., 2013).
Because our data suggest that ABL1 is involved in NRP1-
mediated angiogenic processes, we also compared the retinal 
vascular phenotype of Imatinib-treated mice to that of 
endothelial-specific Nrp1 mutants. For this experiment, we 
treated Cre-positive and Cre-negative littermates with tamoxifen 
in a regimen similar to that used for Imatinib. We observed a sig-
nificant reduction in both tip cell density and vascular branch 
points in mutants, similar to Imatinib-treated mice (Fig. 7 G).
Based on the in vitro and in vivo data we have described 
here, we conclude that NRP1 facilitates angiogenesis in re-
sponse to integrin ligands via ABL1-mediated PXN phos-
phorylation and actin remodeling. Because this pathway 
operates independently of VEGF and VEGFR2, NRP1 plays 
a dual role in angiogenesis and vascular morphogenesis by in-
dependently promoting ECM-stimulated and growth factor–
induced signals in ECs (Fig. 7 H). In agreement, vascular 
extension is more severely inhibited in EC-specific Nrp1 
knockout compared with Imatinib-treated retinas (reduction 
in vascular extension compared with littermate controls: 32 ± 
4% for endothelial Nrp1 knockouts vs. 14 ± 1% for Imatinib-
treated mice).
Imatinib treatment decreases pathological angiogenesis
To assess the relevance of the FN-induced NRP1–ABL1 path-
way for pathological vessel growth, we used a mouse model of 
oxygen-induced retinopathy (OIR; Connor et al., 2009). In 
this model, the sequential exposure of mouse pups to hyper-
oxia followed by normoxia leads to the formation of retinal 
neovascular lesions that resemble those observed in PDR pa-
tients and in babies with ROP, which arises after moving them 
out of incubators with high oxygen tension (Connor et al., 
2009). Specifically, the exposure of neonatal mice to hyperoxia 
from P7 to P12 induces vasoobliteration of central retinal cap-
illaries, which causes central retinal hypoxia on return to room 
air. The ensuing up-regulation of VEGF and other proangio-
genic factors then activates angiogenesis, but this process fails to 
effectively revascularize the retina and instead leads to abun-
dant tuft-like vascular malformations that protrude into the 
vitreous (Smith et al., 1994). Immunostaining of flat-mounted 
retinas on P17, 5 days after return to room air, showed that 
these neovascular tufts were FN positive (Fig. 8 A), suggesting 
that OIR is a suitable model to examine the role of NRP1 and 
ABL1 in ECM-mediated angiogenesis pathways. In agree-
ment, Imatinib treatment of mouse pups from their return to 
normoxia until P17 significantly reduced revascularization of 
avascular areas (AV; Fig. 8, B and C) and effectively inhibited 
the formation of neovascular tufts (Fig. 8, B–D).
In agreement with ABL1 acting downstream of NRP1, a 
reduction in both revascularization of avascular areas and neo-
vascular tuft formation was also seen in conditional endothelial 
To examine if ABL1 was also required for PXN phos-
phorylation in retinal ECs, we treated neonates with Imatinib 
or vehicle (Fig. 6, G and H). Single confocal slices showed that 
pPXN staining was reduced in P6 retinas after 2 days of treat-
ment (Fig. 6 G), as observed for NRP1 mutants. To quantify 
pPXN specifically in ECs, we again isolated IB4-positive areas 
with a virtual mask (Fig. 6 G, right) and found that endothelial 
pPXN pixel intensity was significantly reduced after Imatinib 
treatment (Fig. 6 H). ABL1 therefore promotes PXN phos-
phorylation in angiogenic ECs in vivo, similar to NRP1 and 
as observed for FN-stimulated ECs in vitro.
ABL1 activation is essential for physiological angiogenesis 
in the retina
Because ABL1 is involved in NRP1-mediated actin remodel-
ing, cell migration, and PXN phosphorylation, we investi-
gated next if it is also essential for blood vessel growth in vivo. 
IB4 labeling showed reduced vascular extension and network 
density in retinal flat mounts of P6 Imatinib-treated com-
pared with vehicle-treated mice (Fig. 7 A). Quantitation con-
firmed a small but significant reduction in vascular extension 
across the retina (Fig. 7 B), as previously reported for loss of 
astrocyte FN (Stenzel et al., 2011). In agreement, FN immuno-
staining showed reduced astrocyte FN deposition ahead of 
the vascular front (Fig. 7, C and D), likely due to Imatinib tar-
geting of PDGFR signaling in astrocytes (Buchdunger et al., 
2002). In contrast, we observed abundant FN deposition around 
retinal vessels in both control and Imatinib-treated mice, with 
no difference in FN pixel intensity in IB4-positive areas (Fig. 7, 
C and D). Vascular FN assembly was therefore not compro-
mised by ABL1 targeting.
High magnification images of the retinal vascular front in 
control and Imatinib-treated mice showed that vessels had 
sprouted and formed numerous tip cell filopodia (Fig. 7 E), 
consistent with the concept that VEGF gradients rather than 
matrix pathways drive these processes (Ruhrberg et al., 2002; 
Gerhardt et al., 2003). However, sprouts in Imatinib-treated 
mice appeared longer and wider, with fewer lateral protru-
sions connecting to neighboring sprouts (Fig. 7, E and F, ar-
rows), and filopodia often appeared thin, wavy, and misoriented 
(Fig. 7 E, arrowheads). This phenotype agrees with a role for 
the NRP1–ABL1 complex in endothelial actin remodeling 
(Fig. 1). Moreover, the filopodia defects resemble those previ-
ously seen at the retinal vascular front of mice with a genetic 
lack of astrocyte FN (Stenzel et al., 2011). Yet loss of astrocyte 
FN in itself does not impair vessel sprouting and branching 
(Stenzel et al., 2011), suggesting that the more severe vascular 
defects of Imatinib-treated retinas are due to an EC-autonomous 
role for ABL1.
To further define the vascular defects caused by ABL1 in-
hibition, we compared vessel sprouting and branching in mice 
treated with Imatinib for different times (Fig. 7, F and G). 
Quantitative analysis revealed significantly fewer tip cells, de-
fined by the presence of filopodial bursts at the vascular front 
(Fig. 7 G). Consistent with reduced tip cell density and im-
paired lateral sprout extension, we also observed a significant 
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pathways in postnatal angiogenesis (reduction in neovascular 
tuft formation compared with littermate controls: 60 ± 13% 
for endothelial Nrp1 knockouts vs. 28 ± 10% for Imatinib-
treated mice; Fig. 7 H).
Finally, we assessed the efficacy of Imatinib in targeting 
angiogenesis in the ear wound healing model (Fig. 8 G), in 
Nrp1-null mutants treated with a tamoxifen regimen analo-
gous to that used for Imatinib treatment (Fig. 8, E and F). Even 
though the vascular OIR phenotype of Nrp1 mutants was 
similar to that of Imatinib-treated mice, the reduction in neo-
vascular growth was greater, consistent with a dual role for 
NRP1 in ECM-stimulated ABL1 and VEGF-induced VEGFR2 
Figure 7. ABL1 is essential for vessel spouting and 
branching in the retina. (A and B) P6 retinal vascula-
ture of mice treated with vehicle or Imatinib from P2 to 
P5 was immunolabeled for IB4. Bar, 1 mm. Vascular 
extension from the retinal center to the vascular front is 
indicated with red arrows. (B) Vascular extension after 
Imatinib treatment was quantified as the distance of  
the IB4-positive front from the retinal center relative to 
the retinal radius (vehicle, n = 7 mice; Imatinib, n = 4 
mice; **, P < 0.01, Student’s t test). Error bars show SD.  
(C–E) P6 retinal vasculature of mice treated with vehicle 
or Imatinib from P2 to P5 was immunolabeled for IB4 
and FN. Bars: (C) 200 µm; (E) 50 µm. Note reduced FN 
staining of astrocyte processes ahead of the vascular 
front (), whereas the vasculature was prominently 
stained for FN. (D) Quantification of FN pixel intensity in 
Imatinib-treated retinas in 0.06-mm2 areas of astrocyte 
networks ahead of the vascular front (fold change com-
pared with controls; n = 3 mice each; *, P < 0.05, Stu-
dent’s t test) and in vascular areas, isolated with an 
IB4-guided IMARIS mask (FN relative to IB4 pixel inten-
sity; n = 3 mice each; P > 0.05, Student’s t test). Error 
bars show SD. Higher magnification of the areas indi-
cated with dotted squares in C demonstrates abnormal 
filopodia and sprout morphology in Imatinib-treated 
retinas. The IB4 single channel is shown in grayscale 
below each panel after contrast enhancement to high-
light filopodia. The arrow indicates an abnormally long 
and wide sprout without lateral protrusions or connec-
tions. Examples of abnormally thin, wavy, and misori-
ented filopodia are indicated with arrowheads. Note that 
the interaction of tip cells with microglia (wavy arrow) is 
not prevented by Imatinib treatment. (F and G) IB4-
labeled P6 retinal vasculature of mice treated with ve-
hicle or Imatinib by daily injections on P4 and P5 or 
from P2 to P5. Bar, 200 µm. Examples of abnormally 
long and wide sprouts without lateral protrusions or 
connections are indicated with arrows. (G) Quantifica-
tion of filopodial bursts per vascular front length as an 
indicator of tip cell number, and quantification of 
branch points behind the vascular front (vehicle, n = 7 
mice, vs. Imatinib P4-5, n = 3 mice, or Imatinib P2–5,  
n = 4 mice; ***, P < 0.001 vs. vehicle control, ANOVA with 
Tukey’s comparison test; #, P < 0.05 for P4–5 vs. P2–5 
treatment, Student’s t test; P2–5 tamoxifen-injected 
Nrp1fl/fl mice lacking Cre, n = 8, or expressing Pdgfb-
iCre-ERT2-Egfp, n = 6; *, P < 0.05; ***, P < 0.001 versus 
control, Student’s t test). Error bars show SD. (H) Sche-
matic representation of the NRP1–ABL1–PXN pathway 
and its synergism with known VEGF signaling pathways 
transduced by VEGFR2.
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day 3 until day 20 after ear punch inhibited wound closure, 
with a significantly larger wound diameter at both 14 and 21 d 
compared with vehicle-treated controls (Fig. 8, H and J). 
which the healing of ear punch injuries depends on neoan-
giogenesis (Cho et al., 2006) and the wound margin is rich in 
FN (Fig. 8 H). Daily Imatinib treatment of adult mice from 
Figure 8. Imatinib and endothelial NRP1 targeting inhibit pathological angiogenesis in mouse models of retinopathy and ear wound healing.  
(A) Immunostaining of a P17 wild-type mouse retina for FN together with IB4 after sequential exposure to 7 d of normoxia, 5 d of hyperoxia, and 5 d of normoxia. 
The area indicated with a square is shown in higher magnification adjacent to the first panel as double label and single channels. Bar, 1 mm. (B) Immunostaining for 
collagen IV together with IB4 of P17 retinas from mice treated with vehicle (control) or Imatinib by daily injections after return from hyperoxia to normoxia  
(P13–16). Pseudocoloring highlights AV (white) and neovascularization (NV, red). Bar, 1 mm. (C–F) Quantitation of AV and NV area in Imatinib-treated relative to 
vehicle-injected littermates (C and D; fold change; n = 8 retinas each) and in tamoxifen-injected Nrp1fl/fl mice lacking or expressing Pdgfb-iCre-ERT2-Egfp (E and F; 
fold change; n ≥ 5 retinas each). Asterisks indicate statistical significance: *, P < 0.05; **, P < 0.01; ***, P < 0.001, Student’s t test. Error bars show SD. (G–J) To exam-
ine angiogenesis-dependent wound healing in the ear of vehicle- and Imatinib-treated mice between the day of injury (day 0, D0) and day 21, the punch wound 
was imaged on days 0 and 21 (G; bar, 2 mm) and immunostained for FN together with PECAM and DAPI in 40-µm ear sections on day 21 (H and I; bar, 200 µm). 
Higher magnifications of the areas indicated with dotted squares in H and I are shown in H and I. Note the reduced number of blood vessels at the wound margin 
after Imatinib treatment (). (J) Quantitation of wound diameter in vehicle and Imatinib-treated mice on days 0, 7, 14, and 21 after wounding (vehicle, n = 3 mice; 
Imatinib, n = 4 mice; *, P < 0.05; **, P < 0.01, Student’s t test for vehicle vs. Imatinib-treated mice at days 14 and 21). Error bars show SEM.
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Although FN deposition at the wound was not obviously af-
fected by Imatinib treatment, blood vessel density in the 
wound margin was reduced (Fig. 8, H–I). Imatinib therefore 
targets pathological vessel growth in both the eye and skin.
DISCUSSION
In vertebrates, organ formation and homeostasis require the 
delivery of oxygen and nutrients through blood vessel net-
works, which form in response to signals provided by the vas-
cular endothelial growth factor VEGF (Ruhrberg, 2003). 
VEGF-driven vascular morphogenesis entails the processes of 
vasculogenesis, angiogenesis, and arteriogenesis, which all rely 
on signal transduction by the VEGF receptor tyrosine kinase 
VEGFR2 (Koch et al., 2011). However, it is poorly under-
stood how VEGF signaling is integrated with other signaling 
pathways to ensure that these complementary processes take 
place in appropriate contexts (Carmeliet and Jain, 2011). We 
show here that the VEGF receptor NRP1 has an unexpected 
role in a non-VEGF–driven angiogenesis pathway that is ac-
tivated by ECM signals and involves the tyrosine kinase ABL1. 
The discovery of this pathway has important implications 
for our understanding of both physiological and pathological 
vessel growth.
The coactivation of VEGF-induced and ECM-stimulated 
signaling pathways benefits ordered blood vessel growth in 
complex tissues. Thus, it was previously shown that endothe-
lial tip cells extend filopodia to sense VEGF gradients and to 
align themselves along matrix templates for directional mi-
gration (Ruhrberg et al., 2002; Gerhardt et al., 2003; Uemura 
et al., 2006; Stenzel et al., 2011). Moreover, signaling responses 
induced by ECM-bound VEGF165 involve integrin activa-
tion and differ mechanistically from those induced by soluble 
VEGF165 (Chen et al., 2010). However, the functional sig-
nificance of NRP1’s ability to associate with integrins inde-
pendently of VEGFR2 (Soker et al., 2002; Fukasawa et al., 
2007; Robinson et al., 2009; Valdembri et al., 2009) was not 
previously understood. We demonstrate here that NRP1 pro-
motes integrin ligand-induced EC motility in a VEGFR2- 
independent mechanism that involves ABL1-dependent PXN 
phosphorylation, focal adhesion formation, and actin remod-
eling. We further show that this pathway is essential for nor-
mal vessel sprouting and vascular plexus formation in vivo. 
NRP1 therefore has a dual role in ECs by contributing to both 
VEGF-dependent VEGFR2 activation and ECM-stimulated 
but VEGF/VEGFR2-independent signaling via ABL1.
The novel proangiogenic NRP1 function we have identi-
fied differs fundamentally from prior models, which proposed 
that endothelial NRP1 acts exclusively as a VEGF coreceptor 
to enhance VEGFR2 signaling. Collectively with recent find-
ings that NRP1 associates with VEGFR2 to stimulate VEGF-
induced arteriogenesis (Lanahan et al., 2013), endothelial 
NRP1 appears to activate specific tyrosine kinase pathways 
in a context-dependent fashion to regulate vascular morpho-
genesis. The existence of an ABL1-dependent but VEGFR2-
independent role for NRP1 in angiogenesis may also explain 
why blood vessel growth is affected more severely by loss of 
NRP1 than loss of NRP1-binding VEGF isoforms (Ruhrberg 
et al., 2002; Gerhardt et al., 2004; Raimondi and Ruhrberg, 
2013), why the loss of VEGF binding to NRP1 causes milder 
embryonic vascular defects than loss of NRP1 (Fantin et al., 
2014), and why anti-NRP1 and anti-VEGF treatments syn-
ergize to block angiogenesis-dependent tumor growth (Pan 
et al., 2007a). Importantly, our finding that NRP1 mediates 
ABL1 signaling to regulate actin cytoskeleton and cell migra-
tion in response to extracellular signals has far reaching impli-
cations beyond understanding angiogenesis, as NRP1 is 
important for the behavior of diverse cell types, including 
immune cells, neural crest cells, neurons, and tumor cells.
VEGFR2-independent functions of NRP1 in ECs in vitro 
have previously been ascribed to NRP1 cytoplasmic domain 
signaling. For example, the extracellular part of the EGF 
receptor, when linked to the NRP1 transmembrane and cy-
toplasmic domains, enables EGF-stimulated EC migration 
(Wang et al., 2006). The cytoplasmic NRP1 domain also pro-
motes FN fibrillogenesis in arterial ECs by regulating endo-
somal trafficking of activated 51 integrin (Valdembri et al., 
2009) and is involved in ABL1-mediated FN fibrillogenesis 
in myofibroblasts (Yaqoob et al., 2012). However, NRP1 cy-
toplasmic domain–mediated signal transduction pathways or 
integrin endocytosis are unlikely to play major roles in angio-
genesis because genetic mouse studies showed that this NRP1 
domain is dispensable for physiological and pathological an-
giogenesis (Fantin et al., 2011; Lanahan et al., 2013). Instead, 
NRP1 contributes to angiogenesis solely via its membrane-
tethered extracellular domain (Fantin et al., 2011). Our finding 
that NRP1 promotes matrix signaling to enhance angiogen-
esis therefore agrees with prior observations that the extracel-
lular rather than intracellular NRP1 interacts with 51 
integrin (Fukasawa et al., 2007; Valdembri et al., 2009). Because 
the NRP1 extracellular domain complexes with integrins, 
but the NRP1 cytoplasmic tail is not required for angiogene-
sis, NRP1 most likely associates with ABL1 indirectly, possi-
bly via integrins, as they are known to recruit ABL1 (Cui et al., 
2009; Baruzzi et al., 2010).
The NRP1 dependency of FN-stimulated EC motility 
and migration was reflected in the defective activation of sev-
eral previously identified integrin targets in NRP1 knock-
down cells, including PLC1, ABL1, and PXN. However, 
targeting the FN-stimulated NRP1–ABL1 pathway impaired 
retinal angiogenesis more severely than deleting astrocytic FN 
or single integrins (Stenzel et al., 2011). The greater depen-
dency of angiogenesis on NRP1 than on individual ECM 
components or different integrins may be explained by the 
partial redundancy of proangiogenic matrix components for 
at least some signaling responses (Stenzel et al., 2011) and the 
presence of multiple endothelial FN receptors, including 
51 and v3 (Dejana et al., 1990). Moreover, NRP1 can 
itself act as an adhesion receptor (Shimizu et al., 2000).
Our study identified endothelial NRP1 as a bimodal reg-
ulator of vascular morphogenesis that regulates ABL1-mediated 
signal transduction and actin remodeling during angiogenesis, 
even though it promotes VEGFR2 trafficking and signaling 
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Cell migration assay. HDMECs were transfected with siRNA and 
MLECs treated with adenovirus before overnight serum starvation and then 
plated onto FN-coated transwell inserts (8.0 µm pores, 10 mm diameter; 
Nunc) that had been preincubated with MV2 containing 0.5% BSA (HD-
MECs) or DMEM containing 0.5% BSA (MLECs). After 4 h, cells on the 
upper face of the insert were removed with a cotton bud, while transmi-
grated cells on the underside were fixed with 4% formaldehyde in PBS for 
10 min and stained with 0.1% crystal violet solution for 10 min. Images were 
acquired with a phase-contrast light microscope using a c-plan 10×/0.22 
objective (Leica). Transmigrated cells in duplicate inserts were counted in a 
minimum of five images per insert in three independent experiments.
Random motility. HDMECs were transfected with siRNA, serum-starved 
overnight 56 h after transfection, and then detached and seeded in duplicates 
into 6-well plates that had been coated overnight with 10 µg/ml FN. Cells 
were then imaged in an environmental chamber maintaining a 5% CO2 atmo-
sphere at 37°C with a 10× phase contrast objective at 2-min intervals for 200 min 
using an inverted phase contrast microscope (Axiovert-200M; Carl Zeiss). The 
motility of 25 cells per each condition from two experiments was analyzed 
using the ImageJ MTtrackJ extension module (National Institutes of Health).
Phosphokinase antibody array. HDMECs were transfected with siRNA. 
56 h after transfection, cells were serum-starved overnight and then stimulated 
with 50 ng/ml VEGF165 for 10 min or detached using 0.5× trypsin/EDTA 
(PAA), resuspended in MV2 serum-free media, and plated for 30 min on tis-
sue culture plates coated with 10 µg/ml FN. ECs were lysed as described in 
Immunoblotting and immunoprecipitation and phosphokinase antibody array 
was performed according to the manufacturer’s instructions (R&D Systems).
Gene expression. mRNA was extracted using the RNeasy system (QIA-
GEN). cDNA was prepared using Superscript II reverse transcription (Invitro-
gen) and amplified with (SYBR Green; Applied Biosystems) and the following 
oligonucleotide primers: NRP1, 5-GAAAAATCGAATGCTGAT-3 and 
5-AATCCGGGGGACTTTATCAC-3; ABL1, 5-GAGGGCGTGTG-
GAAGAAATA-3 and 5-GGTAGCAATTTCCCAAAGCA-3; VEGFR2, 
5-AGATGGTGTAACCCGGAGTG-3 and 5-ACATGTCAGCGTTT-
GAGTGG-3; and GUS, 5-AAACGATTGCAGGGTTTCAC-3 and 
5-CTCTCGTCGGTGACTGTTCA-3. Gene expression was analyzed with 
the quantitative 7500 Real-Time PCR System (Applied Biosystems). Data anal-
ysis was performed using the SDS software (version 2.3; Applied Biosystems).
Immunoblotting and immunoprecipitation. Cells were lysed with lysis 
buffer (50 mM Tris-HCl, pH 7.4, 5 mM EDTA, 0.1% NP-40, and 250 mM 
NaCl) in the presence of protease inhibitor cocktail 2 and phosphatase in-
hibitor cocktail (Sigma-Aldrich). Lungs from P7 mice were lysed in GL35 
(Cytoskeleton, Inc). 25 µg of protein was resuspended in Laemmli sample 
buffer, denatured for 5 min, separated by SDS-PAGE, and transferred to ni-
trocellulose membrane (Whatman).
Protein extracts were analyzed by SDS-PAGE and transferred to nitro-
cellulose membrane (Whatman) for immunoblotting with the following pri-
mary antibodies: rabbit anti-GAPDH (Abcam), goat anti-NRP1 C-19 (Santa 
Cruz Biotechnology, Inc.) or AF566 (R&D Systems); mouse anti-ABL1 
(BD); rabbit anti-pCRKL (Y207), rabbit anti-pKDR (Y1175) or KDR, rab-
bit anti-pPXN (Y118), rabbit anti-pAKT (S473) or AKT, or rabbit anti-
pERK1/2 or ERK1/2 (Cell Signaling Technology).
Immunoprecipitation. Serum-starved ECs were detached with 0.5× 
trypsin/EDTA and lysed or seeded into FN-coated plastic dishes for the in-
dicated times before lysis. In some experiments, ECs were treated with 
10 µM Imatinib (Glivec; Cambridge Bioscience) for 30 min before and during 
FN stimulation. ECs were lysed in 50 mM Tris, pH 8.0, 50 mM KCl, 1% 
(vol/vol) NP-40 in the presence of protease inhibitor cocktail 2 and phos-
phatase inhibitor cocktail. 1 mg of protein was incubated with 3 µg goat 
anti-NRP1 (Fantin et al., 2010), rabbit anti-ABL1 (Roig et al., 2000), or 
control goat or rabbit IgG (Santa Cruz Biotechnology) and then with 30 µl 
during arteriogenesis. In addition to regulating physiological 
vessel growth, the NRP1–ABL1 pathway promotes vascular 
pathology that can be inhibited by treatment with Imatinib, a 
small molecule inhibitor of ABL1, or through the genetic ab-
lation of NRP1 in ECs; thus, both approaches significantly 
and similarly reduced vessel growth in a mouse model of 
human retinopathy. Targeting NRP1-mediated ABL1 signal-
ing might therefore provide a novel therapeutic opportunity 
to enhance the efficacy of current anti-angiogenic therapies 
that focus on manipulating VEGF signaling through VEGFR2, 
for example to inhibit tumor angiogenesis or neovascular eye 
disease. In particular, the FDA-approved drug Imatinib might 
provide a complementary treatment to improve the respon-
siveness of patients to anti-angiogenic therapies, for example 
in metastatic colon cancer, PDR, or AMD. Additionally, Ima-
tinib treatment may be beneficial for patients with cancers 
that are fuelled by vasculature that is resistant to anti-VEGF 
therapy. As shown in this preclinical study, Imatinib might be 
delivered systemically to treat vascular eye pathology to cir-
cumvent complications of intravitreal administration of anti-
VEGF therapies, such as increased intraocular pressure or 
endophthalmitis. In conclusion, the unexpected finding that 
NRP1 promotes angiogenesis in a VEGFR2-independent fash-
ion via ABL1 supports a model in which NRP1-mediated ECM 
signaling proceeds independently of, but synergistically with, 
VEGFR2-mediated growth factor signaling to drive angio-
genic tissue invasion in development and disease (Fig. 7 H).
MATERIALS AND METHODS
Cell culture, transfection, and adenovirus infection. HDMECs (Pro-
mocell) were cultured in MV2 media with supplements (Promocell). HUVECs 
(Promocell) were cultured in EBM2 media (Lonza) containing 10% FBS 
(Life Technologies), 300 µg/ml EC growth supplement (ECGS; Sigma- 
Aldrich), and 1 µg/ml hydrocortisone (Sigma-Aldrich). Cells were trans-
fected with lipofectamine RNAIMAX using SMARTpool siRNA targeting 
NRP1, VEGFR2, or ABL1 (Dharmacon), or Silencer negative control siRNA 
(Applied Biosystems). For overexpression studies, HDMECs were transfected 
with Lipofectamine according to the manufacturer’s protocol. In some ex-
periments, cells were incubated with 10 µM Imatinib (Cambridge Biosci-
ence), a concentration known to effectively target ABL1 kinase (Chislock 
et al., 2013). In some experiments, cells were stimulated with 50 ng/ml 
VEGF165 for the indicated times. Primary MLECs were isolated from 
mice between 1 and 2 mo of age by magnetic-activated cell sorting (MACS) 
with PECAM antibodies (BD). MLECs were cultured on 10 µg/ml FN in 
DMEM-GlutaMAX supplemented with 20% FBS, nonessential amino 
acids (Life Technologies), and ECGS. MLECs from Nrp1fl/fl conditional null 
mice were infected with adenovirus-expressing CRE recombinase or with 
control virus–expressing GFP, incubated for 24 h in culture media, washed 
in PBS, and cultured in fresh media for 48 h before migration and immuno-
blotting experiments.
Adhesion assay. HUVECs or HDMECs transfected with targeting or con-
trol siRNA were detached with trypsin, resuspended in MV2 medium con-
taining 0.5% BSA, and incubated at 37°C for 1 h on a rotating wheel. 10,000 
cells/well were seeded on 96-well tissue culture plates (Nunc; Thermo Fisher 
Scientific) coated overnight with 10 µg/ml FN in PBS or, as an internal con-
trol, PBS containing 1% BSA, for the indicated times in triplicate, washed in 
PBS, fixed in 4% formaldehyde in PBS, and stained with 0.1% crystal violet 
for 30 min. After washing three times with PBS for 15 min, dye was extracted 
with 10% SDS in PBS for 15 min on an orbital shaker to determine absor-
bance at 570 nm.
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